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1. Introduction 
Serine proteases have long been recognized as major players in a wide range of biological 
processes including cell signaling, cell cycle progression, digestion, immune responses, 
blood coagulation and wound healing. Their role in the physiology of many human 
diseases, ranging from cancer and inflammatory disorders to degenerative diseases, now 
represents an increasingly important feature of this family of enzymes. Proteases are tightly 
controlled through a number of different mechanisms, including regulation of gene 
expression, recognition of the substrate by the active site, activity regulation by small 
molecules, changes in cellular location, post-translational modifications, interaction with 
other proteins and/or through inhibition of proteolysis by protease inhibitors (PI) [1-3]. This 
last mechanism usually involves competition with substrates for access to the active site of 
the enzyme and the formation of tight inhibitory complexes. An understanding of the role 
played by serine proteases and their specific inhibitors in human diseases offers novel and 
challenging opportunities for preventive and/or therapeutic intervention [4]. 
Within this framework, there is a growing interest in naturally-occurring serine protease 
inhibitors of the Bowman-Birk family due to their potential chemopreventive and/or 
therapeutic properties which can impact on several human diseases, including cancer, 
neurodegenerative diseases and inflammatory disorders. In light of the Food and Drug 
Administration (FDA) approval for trials of Bowman-Birk inhibitors (BBI) concentrate 
(BBIC), a protein extract of soybean (Glycine max) enriched in BBI, as an ‘Investigational 
New Drug‘, human trials have been completed in patients with benign prostatic hyperplasia 
[5], oral leukoplakia [6-8] and ulcerative colitis [9] (Table 1). Although, in most of these 
cases, the intrinsic ability of BBI to inhibit serine proteases has been related to beneficial 
health properties, the mechanisms of action and the identity of their therapeutic targets are 
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largely unknown. In this chapter, we describe the emerging evidence for the positive 
contribution of BBI from legumes to disease prevention and therapy. 
 
Disease Type of trial Experimental design Main results Ref. 
Benign 
prostatic 
hyperplasia   
Phase I trial Duration: 6 months. 
19 patients. Daily 
doses up to 800 CIU a
Significant decrease (up to 43 %) in 
PSAb levels after treatment. 
Decrease of prostate volume in 
patients. No dose-limiting toxicity 
[5]    
Oral 
leukoplakia   
Phase I trial Duration: 1 month. 24 
patients. Single daily 
dose: 800 CIU
BBI was well tolerated. No clinical 
evidence of toxicity or any adverse 
reaction        
[6] 
 Plase II trial Duration: 1 month. 32 
patients. 
Administration: twice 
daily, up to 1066 CIU 
31 % of patients achieved clinical 
response and lesion area decreased 
after treatment. Dose-dependent 
effect. BBI was non-toxic. The 
positive clinical effect of BBIC 
could be due to the inhibition of 
serine proteases involved in the 
cleavage of neu-oncogen protein on 
the cell surface, preventing the 
release of the extracellular domain 
of the protein into the bloodstream 
[7] 
 Double-blind
randomized, 
Placebo-
controlled 
phase IIb 
trial 
148 patients. Daily 
dose: 600 CIU 
Although this study has not been 
completed yet, preliminary results 
suggest that BBIC is not fully 
effective in patients       
[8] 
Ulcerative 
colitis 
A 
randomized,
double 
blind, 
placebo-
controlled 
trial
12 weeks of therapy. 
28 patients. Daily 
dose: 800 CIU 
BBIC might be associated with the 
regression of disease without 
apparent toxicity or adverse side 
effects 
[9] 
aCIU: chymotrypsin inhibitory units; bPSA: prostate specific antigen 
Table 1. Clinical trials utilizing a protein extract of soybean enriched in Bowman-Birk inhibitors (BBIC)   
2. The Bowman-Birk family 
2.1. Sources and occurrence 
Plant PI can be categorized into at least 12 different families with 10 of these targeting serine 
proteases and adopting the standard mechanism of inhibition [10]. Members of the 
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Bowman-Birk family are canonical serine PI of low molecular weight, being particularly 
abundant in legume seeds. Soybean BBI represent the most extensively studied members of 
the Bowman-Birk family, but related BBI from other dicotyledonous legumes [including 
chickpea (Cicer arietinum), common bean (Phaseolus vulgaris), lentil (Lens culinaris) and pea 
(Pisum sativum)] and from monocotyledonous grasses (Poaceae) [including wheat (Triticum 
aestivum), rice (Oryza sativa) and barley (Hordeum vulgare) species], have been identified and 
characterized.  
The BBI that are expressed in seeds are the products of multi-gene families. Several 
isoinhibitors have been identified in seeds of individual species [11, 12]. The expression of 
distinct genes, together with the post-translational modifications of primary gene products, 
combine to give rise to the array of BBI-like variants described for many legume species. 
Variants in overall and active site sequences, size, functional properties and spatial pattern 
of expression have been described [13]. As a result, qualitative and quantitative differences 
in protease inhibitory activities have been shown in comparisons of pea genotypes [14, 15]. 
The close linkage of the genes encoding BBI, demonstrated for a number of legume species 
[16], allows the development of near-isolines having distinct haplotypes. In pea, the co-
segregation of quantitative and qualitative variation has been used to develop a series of 
near-isolines, which have allowed the biological significance of a five-fold variation in seed 
protease inhibitory activity to be investigated at the level of ileal digestibility [17, 18]. These 
lines now facilitate related studies on the positive contribution of seed BBI to the prevention 
of disease states. 
The occurrence of BBI in soy foods (soymilk, soy infant formula, defatted soy meal, 
oilcake, tofu, soybean protein isolate and soybean protein concentrate, among others) is 
noteworthy, where BBI may be present in different amounts. The soy varieties used, the 
products themselves and the technological processes used in their preparations all 
contribute to variation in BBI concentration. In order to quantify BBI in soy foods, 
enzymatic and immunological methods have been developed; however, no 
comprehensive information on the concentration of BBI in soy foods is available currently. 
Recently, Hernández-Ledesma et al. [19] reported BBI concentrations in 12 soymilk 
samples ranging from 7.2 to 55.9 mg BBI/100 mL of soymilk, while BBI was not detected in 
a soy-based infant formula. BBI was also reported in tofu samples, with concentrations 
ranging between 2.9 and 12.4 mg/100 g product. Since BBI could not be detected in natto 
and miso samples, it may be assumed that BBI were degraded during the fermentation 
process.  
2.2. Inhibitory properties 
The inhibitory activity of BBI is due to the formation of stable complexes between the 
inhibitor and target proteases. The conformation of the reactive site loop is complementary 
to the active site of the protease inhibited and allows BBI to bind tightly to proteases in a 
substrate-like manner [20, 21]; the resulting non-covalent complex renders the target 
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protease inactive. Upon complex formation, BBI may be cleaved very slowly (low Kcat). In 
legumes, the enzyme inhibitory activity is associated with two subdomains of the BBI, 
located at opposite sides of the molecule; each canonical loop is contained within a 
nonapeptide region joined via a disulphide bond between flanking cysteine residues. The 
double-headed BBI have a characteristic highly conserved array of intra-molecular 
disulphide bridges occurring among 14 Cys residues [22]. The two binding loops can each 
inhibit independently and simultaneously an enzyme molecule, which may be the same or 
distinct types of enzyme [13]. The specificity of each reactive site is determined by the 
identity of the amino acid residue in position P1 [23]. In double-headed BBI, the first active 
site is usually involved in trypsin inhibition, with the P1 position being occupied by Arg or 
Lys. The presence of an Ala residue at the P1 position has been reported to be associated 
with inhibition of elastase [24]. Chymotrypsin is often the target of the second inhibitory 
domain as it has a hydrophobic amino acid in its P1 position [13, 25]. Additional residues 
adjacent to the reactive site peptide bond (P1-P1´) can have a significant effect on the affinity 
of BBI for particular protease targets [13]. BBI from legumes include potent inhibitors of 
both trypsin and chymotrypsin, with Ki values within the nanomolar range reported for 
different members, including soybean [26], pea [27, 28], lentil [29, 30] and lupin (Lupinus 
albus) BBI [31].   
3. Bioavailability and metabolism of BBI 
In order to exert any local or systemic health benefits, dietary BBI must resist degradation 
and maintain biological activity, at least to some extent, after food processing and further 
passage through the gastrointestinal tract (GIT) [22]. BBI from several legume sources 
have been shown to resist thermal treatment (up to 100 °C), under either neutral or acidic 
conditions [32]. Most of the heat-resistant trypsin inhibitory activity in processed legumes 
is attributable to BBI. At temperatures of 80 °C or lower, chickpea BBI were found to be 
stable and their inhibitory activities to be unaffected by thermal treatment [33]. Soybean 
BBI do not lose activity at pH values as low as 1.5 in the presence of pepsin at 37 °C for 2 h 
[34]; these proteins are also stable to both the acidic conditions and the action of digestive 
enzymes under simulated gastric and intestinal digestion [35]. Such stability is associated 
with the rigid structure provided by the seven intra-molecular disulphide bridges that 
maintain the structural and functional features of the binding sites by adding covalent 
attachment to the inhibitor core [10, 36]. BBI are fully inactivated by autoclaving or 
reduction of their disulphide bridges followed by alkylation of the cysteinyl sulfhydryl 
groups [26]. 
The resistance of BBI to extreme conditions within the GIT may favour the transport of 
biologically active BBI across the gut epithelium and could allow their distribution to 
target organs or tissues in order to exert their beneficial effects locally. The uptake and 
distribution of soybean BBI, following oral administration, has been examined in 
rodents. By using [125I] BBI, it was demonstrated that BBI becomes widely distributed in 
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mice 3 h after oral administration [37]. Labelled BBI was detected in the luminal contents 
of the small and large intestine; analysis of tissue homogenates revealed also the 
presence of active BBI in internal organs where soybean BBI have been shown to exert 
anti-carcinogenic effects (see next section). By using inverted sacs from different sections 
of the small intestine, it was demonstrated that active BBI could be transported 
effectively across the gut epithelium. It has been shown that soybean BBI have a serum 
half-life of 10 h in rats and hamsters, and are excreted in urine and faeces [38]. In 
humans, BBI are taken up rapidly and can be detected in the urine within 24-48 h [6]. 
These findings suggest that BBI are absorbed after oral administration and can reach 
several tissues and organs. 
BBI have potential health-promoting properties within the GIT [22]. In vivo studies have 
demonstrated the presence of active BBI in the small intestine. Hajós et al. [39] reported the 
survival (~ 5 % of total ingested) of soybean BBI in an immunological reactive form in the 
small intestine of rats; unfortunately, the inhibitory activities of BBI were not evaluated in 
these experiments. More recently, it has been demonstrated that BBI from chickpea seeds 
can resist both acidic conditions and the action of digestive enzymes, and transit through the 
stomach and small intestine of pigs, generally held as a suitable model for human digestive 
physiology [40]. The presence of active BBI (5-8 % of the total ingested BBI) at the terminal 
ileum revealed the resistance of at least some, or a significant proportion, of these proteins 
to the extreme conditions of the GIT in vivo. Chromatographic, electrophoretic and 
enzymatic data obtained from ileal samples suggested that most of the BBI activity is 
derived from a protein core containing the two binding domains, and resistant to 
proteolysis. In vitro incubation studies of soybean BBI with mixed fecal samples of pigs 
showed that BBI remained active and their intrinsic ability to inhibit serine proteases was 
not significantly affected by the enzymatic or metabolic activity of fecal microbiota [41]. All 
of these results are significant to investigations of the potential uses of BBI in preventive or 
therapeutic medicine. 
4. Chemopreventive properties of Bowman-Birk inhibitors 
Chemoprevention is the use of natural agents or synthetic drugs to halt or reverse the 
carcinogenesis process before the emergence of invasive cancer. The fact that certain dietary 
constituents can exert chemopreventive properties has major public health implications and 
the widespread, long-term use of such compounds should be promoted in populations at 
normal risk, based on understanding the scientific basis of their beneficial effects. In 
particular, BBI have been linked to a possible protective effect against both inflammatory 
disorders and cancer development (Table 2).  
4.1. Colorectal cancer 
Nutritional intervention and/or dietary manipulation have been suggested as key strategies 
to prevent and/or control colorectal carcinogenesis [42, 43], one of the major causes of 
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cancer-related mortality worldwide in both men and women [44]. There is now robust 
preclinical evidence to suggest that dietary BBI from several legume sources can prevent or 
suppress cancer development and associated inflammatory disorders within the GIT [22]. 
Soybean BBI have been reported to be effective at concentrations as low as 10 mg/100 g 
diet, in reducing the incidence and frequency of colorectal tumors, in studies based on the 
dimethylhydrazine (DMH) rat model, where no adverse effect of BBI was documented for 
animal growth or organ physiology [45]. When the inhibitory activity of BBI is abolished, 
any suppressive effect on colorectal tumor development disappears, suggesting that the 
inhibitory properties of BBI against serine proteases may be required for their reported 
chemopreventive properties. Proteases play a critical role in tumorigenesis, where their 
activities become dysregulated in colorectal cancer and neoplastic polyps [46]. In 
particular, serine proteases are key players in several biological functions linked to tumor 
development, including cell growth (dys)regulation and cell invasion as well as 
angiogenesis and inflammatory disorders. Some of these proteases have been reported as 
promising cancer biomarkers [47-49] (Table 3). An understanding of the role played by 
specific serine proteases in the biological processes associated with disease may suggest 
modes of therapeutic intervention [1, 50]. Successful examples of therapeutic intervention 
using PI include ubiquitin-proteasome inhibitors in the treatment of multiple myeloma 
[51]. The ubiquitin-proteasome pathway is essential for most cellular processes, including 
protein quality control, cell cycle, transcription, signalling pathways, protein transport, 
DNA repair and stress responses [52]. Inhibition of proteasome activity leads to 
accumulation of poly-ubiquitinylated and misfolded proteins, endoplastic reticulum 
stress and eventually apoptosis. Although soybean BBI has been demonstrated to inhibit 
the proteasomal activity of MCF7 breast cancer cells (see section 4.4), the proteasomal 
inhibition in colon cancer cells need to be unambiguously demonstrated. Another 
potential therapeutic target of BBI is matriptase (also known as MT-SP1 or epithin), an 
epithelial-specific member of the type II transmembrane serine protease family, which 
plays a critical role in differentiation and function of the epidermis, gastrointestinal 
epithelium and other epithelial tissues. Several studies suggest that matriptase is over-
expressed in a wide variety of malignant tumors including prostate, ovarian, uterine, 
colon, epithelial-type mesothelioma and cervical cell carcinoma [53]. It has been proposed 
to have multiple functions, acting as a potential activator of critical molecules associated 
with tumor invasion and metastasis. MT-SP1 contributes to the upstream activation of 
tumor growth and its progression through the selective degradation of extracellular 
matrix proteins and activation of cellular regulatory proteins, such as urokinase-type 
plasminogen activator, hepatocyte-growth factor/scatter factor and protease-activated 
receptor [54]. Although the ability of soybean BBI to inhibit a secreted form of 
recombinant MT-SP1 has been demonstrated [55], the clinical relevance of such inhibition 
has not been proven yet. The validation of specific serine proteases as BBI targets, 
together with the identification of natural BBI variants, and the design of specific potent 
inhibitors of these proteases, will contribute to the assessment of BBI as colorectal 
chemopreventive agents for preventive and/or therapeutic medicine [22]. 
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Cancer 
type 
BBI source Carcinogen Model system Effect and/or mechanisms of 
action 
Refs. 
Colorectal Soybean DMHa Colon 
carcinogenesis 
in rodents
Reduction of incidence and 
frequency of tumors likely via 
protease inhibition
[45]    
 Soybean DMH Mouse colon 
and anal 
inflammation
Suppression of adenomatous 
tumors of the GIT 
[56] 
 Soybean DSSb Mouse colon 
inflammation 
Suppression of histological 
inflammation parameters, 
lower mortality rate and 
delayed onset of mortality 
[57] 
 Horsegram DMH Colorectal 
carcinogenesis 
Protective role against 
inflammation and pre-
neoplastic lesions
[58] 
 Lentil - Colon cancer 
cells 
Proliferation of HT29 colon 
cancer cells was decreased 
(IC50 = 32 µM), whereas the 
non- malignant fibroblastic 
CCD18Co cells were 
unaffected
[30] 
 Pea - Colon cancer 
cells 
The anti-proliferative effect of 
BBI in colon cancer cells are 
demonstrated 
[15]    
 Soybean - Colon cancer 
cells 
Time- and concentration-
dependent anti-proliferative 
effect on HT29 cells, arrest at 
G0-G1 phase; trypsin- and 
chymotrypsin-like proteases 
are potential targets
[26] 
 Recombi-
nant 
proteins 
- Colon cancer 
cells 
rTI1B, a major BBI isoinhibitor 
from pea, having trypsin and 
chymotrypsin inhibitory 
activity, affected the 
proliferation of colon cancer 
cells; however, a derived 
inactive mutant did not  
show any anti-proliferative 
effect 
[68] 
Gastric Field bean Benzo-
pyrene 
Mouse stomach 
carcinogenesis 
BBI was more effective in 
prevention than in therapeutic 
treatment, with activity 
related to its protease 
inhibitory ability
[100] 
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Cancer 
type 
BBI source Carcinogen Model system Effect and/or mechanisms of 
action 
Refs. 
Breast Black-eyed 
pea 
- Breast cancer 
cells 
BBI induced apoptosis, cell 
death and lysosome 
membrane permeabilization 
[79] 
 Soybean - Breast cancer 
cells 
Proteasome was reported as 
potential therapeutic target in 
MCF-7 cells 
[78] 
Prostate Soybean - Prostate cancer 
cells and rat 
prostate 
carcinogenesis     
BBI exerted chemopreventive 
activity associated with 
induction of connexin-43 
expression and apoptosis 
[76,77] 
 Soybean - Prostate cancer 
xeno-grafts in 
nude mice 
BBI and BBIC inhibited the 
growth of LNCaP cells 
[72] 
 Soybean - Prostate cancer 
cells 
BBI prevented the generation 
of activated oxygen species 
and activated DNA repair 
through a p53-dependent 
mechanism 
[74, 75] 
Oral  Soybean - Oral 
leukoplakia 
BBIC exerted a dose-
dependent reduction in oral 
lesion size in 31% of patients 
without any adverse effects; 
modulation of protease 
activity and neu oncogene 
levels was observed 
[6,7,69] 
aDMH: dimethylhydrazine; bDSS: dextran sulphate sodium  
Table 2. In vitro and in vivo studies showing chemopreventive properties of Bowman-Birk inhibitors 
A strong interest exists in investigating the potential of BBI as anti-inflammatory agents 
within the GIT. In rodents, soybean BBI treatment appears to have a potent suppressive 
effect on colon and anal gland inflammation, following exposure to carcinogenic agents [56], 
or when assessed in an acute injury/colitis model [57]. The protective effect of BBI from 
soybean or those from perennial horsegram (Macrotymola axillare) against inflammation and 
development of pre-neoplastic lesions induced in the DMH mouse model was reported 
recently [58]. Given the lack of toxicity as well as the reported anti-inflammatory properties 
in animals, the potential for BBIC to benefit patients with ulcerative colitis has been 
evaluated. In a randomized double-blind placebo-controlled trial, a dose of 800 
chymotrypsin inhibitor units (CIU) per day over a three-month treatment period was 
associated with a clinical response and induction of remission, as assessed by the Sutherland 
Disease Activity Index score [59], in patients with ulcerative colitis, without apparent 
toxicity [9]. Approximately 50 % of patients responded clinically and 36 % showed 
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remission of disease. Several mechanisms have been proposed to explain the anti-
inflammatory properties of BBI. The ability of BBI to decrease the production and release of 
superoxide anion radicals, mediators of inflammatory processes, in purified human 
polymorphonuclear leukocytes [60] and in differentiated HL60 cells [59] has been reported. 
The decrease in superoxide radical levels may reduce free radical-induced DNA damage 
and transformation to malignant phenotypes. In addition, superoxide radicals can initiate a 
wide range of toxic oxidative reactions, including lipid peroxidation. In this regard, it has 
been demonstrated that BBI can reduce the content of lipid peroxides in irradiated cells in 
vitro [61], a reduction that is presumed to be linked to the anti-inflammatory activity of BBI. 
The role that certain serine proteases play during proteolysis in acute and chronic 
inflammatory processes is well recognized. The ability of soybean BBI to inhibit serine 
proteases involved in inflammatory processes, such as cathepsin G [62, 63], elastase [64] and 
mast cell chymase [64] has been reported. The last enzyme acts as a chemo-attractant and 
may play a role in the accumulation of inflammatory cells during development of allergic 
and non-allergic diseases [65]. The interaction of chymase and BBI may impact on other 
processes involved in anti-inflammatory responses, such as the regulation of collagenase 
[66] and interleukin 1 (IL-1) [67]. Nevertheless, a clear correlation between the inhibition 
of these serine proteases and the anti-inflammatory properties associated with soybean BBI 
has not been demonstrated clearly [22].  
 
Serine 
protease 
Function Pathological process Refs. 
Tryptase Phagocytosis, degradation of 
ECMa compounds, regulation of 
inflammatory responses, blood 
coagulation
Atherosclerosis, asthma, 
inflammatory disorders 
[97, 
98]    
Cathepsin G ECM degradation, migration, 
regulation of inflammatory 
disorders
Inflammation, metastasis [62] 
Matriptase Matrix degradation, regulation 
of intestinal barrier, iron 
metabolism
Pathogenesis of epithelial 
tissues, tumor growth and 
progression
[55] 
Human 
elastase 
Pathogen killing, ECM 
degradation, inflammatory 
disorders
Pulmonary disease, 
inflammation 
[62, 
99] 
Chymase Degradation of ECM 
compounds, regulation of 
inflammatory  responses
Inflammation, asthma, 
gastric cancer 
[64] 
Proteasome Protein degradation, cell 
proliferation, differentiation, 
angiogenesis and apoptosis
Carcinogenesis, 
inflammation, neurodeg-
eneration 
[58, 
78] 
aECM: extracellular matrix  
Table 3. Serine proteases involved in pathological processes as potential therapeutic targets of soybean 
BBI and related proteins (adapted from Clemente et al., 2011 [22]).  
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In previous studies, a significant concentration- and time-dependent decrease in the growth 
of an array of colon cancer cells (HT29, Caco2, LoVo) has been demonstrated in vitro, 
following treatment with BBI variants from several legume sources, including pea, lentil and 
soybean; in contrast, the growth of non-malignant colonic fibroblastic CCD18-Co cells was 
unaffected by BBI [15, 26, 30]. Recently, the anti-proliferative effect of rTI1B, a major pea 
isoinhibitor expressed heterologously in Pichia pastoris, has been evaluated using colon 
cancer cells grown in vitro. Comparisons of the effects of rTI1B with those observed using a 
related synthetic mutant derivative, showed that the proliferation of HT29 colon cancer cells 
was inhibited significantly by rTI1B in a dose-dependent manner, whereas the mutant 
which lacked trypsin and chymotrypsin inhibitory activity did not show any significant 
effect on colon cancer cell growth (Figure 1) [68]. Although the molecular mechanism(s) of 
this chemopreventive activity remains unknown, the reported data indicate that both 
trypsin- and chymotrypsin-like serine proteases involved in carcinogenesis are likely 
primary targets for BBI. 
 
Figure 1. Dose–response effects of rTI1B (closed bars), a major pea isoinhibitor expressed in Pichia 
pastoris, and the corresponding inactive mutant (open bars), having amino acid substitutions at the P1 
positions in the two inhibitory domains, on the in vitro growth of HT29 human colorectal 
adenocarcinoma cells. Growth media were supplemented with rTI1B in the concentration range 15–61 
µM and cells harvested after a period of 96 h. Data are means of at least three independent experiments, 
each having four technical replicates; bars represent standard deviations. Means not sharing superscript 
letters differ significantly (p <0.05; Bonferroni’s test) (Adapted from Clemente et al., (2012) [68]). 
4.2. Oral leukoplakia 
Leukoplakia in the oral cavity is considered a suitable model for the study of 
chemoprevention because the precancerous lesions are readily accessible to visual 
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examination, diagnostic sampling and evaluation of response to treatment. In a Phase I 
clinical trial, no clinical evidence of toxicity or any adverse effect was apparent when BBIC 
was administered as a single oral dose of up to 800 CIU to twenty-four patients with oral 
leukoplakia over one month-period [6]. The study revealed that BBIC was well-tolerated 
and no allergic reactions, gastrointestinal side-effects or other clinical symptoms were 
elicited. In a non-randomized phase IIa clinical trial, treatment with BBIC for one month 
resulted in a dose-dependent reduction in oral lesion size in 31% of patients [7]. The positive 
clinical effect of BBIC was associated with modulation of protease activity and neu oncogene 
levels (as the surrogate endpoint biomarker for the trial) in exfoliated oral mucosal cells [7, 
69]; however, this evidence is indirect and the specific target proteases inhibited were not 
reported. A recent phase IIb randomized, double-blind, placebo-controlled trial involving 
patient treatment with BBIC for six months was performed. Even though this multi-
institutional study has not been completed yet, BBIC does not seem to be fully effective as 
chemopreventive agent for the management of oral leukoplakia [8]. 
4.3. Prostate cancer 
Prostate cancer is the second most frequently diagnosed cancer in men although the 
incidence of cancer varies greatly throughout the world. Dietary habits and lifestyle have 
been identified as major risk factors in prostate cancer growth and progression, suggesting 
that prostate cancer might be preventable [70]. Epidemiological studies have shown an 
inverse association between soy intake and the risk of developing prostate cancer [71]. 
Preclinical and clinical studies have shown the potential chemopreventive properties of BBI 
in prostate cancer. Purified soybean BBI and BBIC have been shown to inhibit the growth of 
LNCaP human prostate cancer xenografts in nude mice [72], and to decrease the growth, 
invasion and clonogenic survival of several human prostate cancer cells [73]. The 
effectiveness of soybean BBI in preventing the generation of activated oxygen species in 
prostate cancer cells [74] and in activating DNA repair through a p53-dependent mechanism 
has been reported [75]. More recently, BBIC has prevented the growth of prostate tumors in 
transgenic rats developing adenocarcinoma, most likely as a consequence of its anti-
proliferative activity via induction of connexin 43 expression [76, 77]. In humans, a double-
blind, randomized, phase I trial was carried out in nineteen male subjects with benign 
prostatic hyperplasia, which is a precursor condition for prostate cancer, and lower urinary 
tract symptoms [5]. In this study, the authors demonstrated that BBIC treatment for six 
months reduced levels of prostate-specific antigen (PSA), a clinical marker for prostate 
cancer, and prostate volume in patients. Additional clinical studies will be necessary to 
determine the potential of BBIC as prostate cancer chemopreventive agent. 
4.4. Breast cancer 
Breast cancer is one of the most frequent cancer types and is responsible for the highest 
mortality rate among women. Novel complementary strategies, including chemoprevention, 
have been suggested. As 125I-BBI, when orally administrated in rodents, has been 
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demonstrated in the bloodstream and distributed through the body [37-38], its 
chemopreventive properties could occur in breast tissue. In vitro studies have reported the 
potential of BBI as chemopreventive agents in breast cancer. Soybean BBI has been shown to 
inhibit, specifically and potently, the chymotrypsin-like proteasomal activity in MCF7 breast 
cancer cells in vitro and in vivo [78]. The proteasomal inhibition was associated with an 
accumulation of ubiquitinylated proteins and the proteasome substrates, p21Cip1/WAF1 and 
p27Kip1; a down-regulation of cyclin D1 and E was also observed. These authors suggested that 
soybean BBI abates proteasome function and, dependent on dose and time, up-regulates MAP 
kinase phosphatase-1 (MKP-1), which in turn suppresses phosphorylation coupled to 
extracellular signal-related kinase activity in MCF7 treated cells. The ability of soybean BBI to 
inhibit the proteasomal chymotrypsin-like activity in intact MCF7 cells suggests that the 
protease inhibitor can penetrate cells and facilitate the inhibition of intracellular target 
proteases. Recent findings have demonstrated that BBI from black-eye pea (Vigna unguiculata) 
induced apoptotic cell death in MCF7 breast cancer cells associated with severe cell 
morphological alterations, including the alteration of the nuclear morphology, plasma 
membrane fragmentation, cytoplasm disorganization, presence of double-membrane vesicles, 
mitochondrial swelling and lysosome membrane permeabilization [79].  
4.5. Radioprotection 
Radiotherapy is used in the treatment of a broad range of malignant tumors with the aim to 
inflict maximal damage on the tumor tissue. Exposure of surrounding normal tissue to 
therapeutic radiation should be minimized to avoid side effects that can have a significant 
impact on general status and quality of life of patients. The use of radioprotective agents to 
reduce the damage in normal tissue may improve the therapeutic benefit of radiotherapy. 
The radioprotective properties of BBI have been tested on cell cultures; so far, no data 
regarding efficacy in humans are available. Soybean BBI have shown potent and selective 
radioprotection of normal tissue in vitro [80] and in vivo [81], without protecting tumor 
tissue. Dittmann et al. [81] showed that soybean BBI increased clonogenic survival after 
irradiation only in cells, either normal or transformed, having a wild-type p53 tumor 
suppressor gene. In a cell line with inducible expression of mutated p53, the radioprotective 
effect of BBI was only detected when the expression of the mutated p53 was switched off 
[75]. The activation of the DNA–repair machinery, induced by pre-treatment of fibroblastic 
cells with soybean BBI, suggests a possible BBI-mediated p53-dependent mechanism for 
radioprotection [82, 83]. Since a high number of tumors have lost p53 function during their 
development, the clinical application of BBI to protect normal tissue from radiation damage 
would effectively improve the therapeutic outcome of radiotherapy.  
The involvement of BBI in radiation-induced signaling cascades, and their role in stabilizing 
a specific tyrosine phosphatase that interferes with the activation of an epidermal growth 
factor receptor in response to radiation exposure, could be responsible for such protection 
[84]. Experiments carried out with linear forms of BBI demonstrated that the secondary 
structure of BBI, required for the protease inhibitory activity, was not necessary for its 
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radioprotective properties [85]. The radioprotective effect of soybean BBI was mainly 
associated with the chymotrypsin inhibitory site [86] and could be mimicked using a 
synthetic linearized nonapeptide (CALSYPAQC), corresponding to the active site for 
chymotrypsin inhibition, but lacking protease inhibitor activity [85]. These observations 
provide opportunities for the use of synthetic peptides for protecting against ionizing 
radiation. BBI, when applied topically, once a day for 5 days, to SKH-1 hairless mice with a 
high risk of developing UV-induced skin tumors, inhibited the formation and growth of skin 
tumors [85]. In addition, topical application of nondenatured soymilk, once a day for a period 
of five days prior to UV irradiation, to mini-swine skin reduced or completely eliminated UV-
induced formation of thymine dimers and apoptotic cells. Finally, BBIC appears to play a 
radioprotective role in radiation-induced cataract formation reducing the prevalence and 
severity of the lens opacifications in mice exposed to high-energy protons [88]. 
5. Beneficial properties of Bowman-Birk inhibitors in non-related cancer 
diseases   
The loss of muscle protein due to inactivity, disease or aging is a process known as muscular 
atrophy or wasting. Skeletal muscular atrophy in response to disuse involves both a decrease 
in protein synthesis and increased protein degradation, predisposing humans to undergo a 
substantial loss of muscle mass. In connection with this, complex proteolytic cascades may 
provide a mechanism for the initiation of protein degradation during atrophy. Dietary 
intervention suggests possible therapeutic strategies via protease inhibition to diminish 
muscular atrophy and loss of strength following unloading. Skeletal muscular atrophy can be 
reproduced experimentally in rodents by hind-limb unloading. Dietary supplementation 
containing 1% BBIC has been reported to inhibit unloading-induced weakness in mice [89], 
promoting redox homeostasis in muscle fibers and blunting atrophy-induced weakness [90]. 
Morris et al. [89] suggested that inhibiting muscle degrading proteases may provide a new 
pharmacological strategy in treating skeletal muscular atrophy; however, such proteases 
remain uncharacterized. More recently, oral administration of BBIC was reported to improve 
muscle mass and function and to modulate pathological processes in the mouse model of 
Duchenne muscular dystrophy (mdx mouse) [91]. Chymase, a serine protease that is released 
from mast cells, is involved in inflammatory processes and is susceptible to inhibition by BBI, 
and hence has been suggested as a BBI target in mdx mice. Additional studies are necessary to 
elucidate the potential therapeutic role of BBI in muscular dystrophy. 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
characterized by progressive demyelination of the brain and spinal cord. Available 
therapeutic treatments have only limited efficacy and show significant side effects. The 
search for novel therapeutic agents that can be administered orally, and act synergistically 
with existing therapies, would be useful for patients with MS. Purified soybean BBI and 
BBIC have been shown to be effective in the suppression of experimental autoimmune 
encephalomyelitis in rodents, a model to study the pathogenic mechanisms of MS and to 
test potential therapies [92]. The oral administration of BBI in mice caused an improvement 
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of several disease parameters (onset, severity, weight loss, inflammation, neuronal loss and 
demyelination), with no apparent adverse effects [93, 94]. Interestingly, BBI ameliorated 
disease, even when treatment was initiated after disease onset, via an IL-10-dependent 
mechanism [94]; the molecular basis for the induction of IL-10 production by BBI remains to 
be elucidated. Recent studies have demonstrated that BBI is responsible for delayed onset of 
disease but did not stop disease development, which became similarly severe in treated 
mice as in control animals [95, 96]. The ability of soybean BBI to delay both inflammatory 
and neurodegenerative aspects of autoimmune encephalomyelitis suggests that it may be 
useful for treating acute MS exacerbations and neurological dysfunction.  
6. Concluding remarks  
In recent years, much effort has focused on clarifying the potential chemopreventive 
properties of BBI. Preclinical and clinical studies have clearly demonstrated that BBI uptake 
is well-tolerated and no side-effects were elicited. This is particularly relevant and lack of 
toxicity is a major consideration, given the necessity for prolonged duration of 
administration. Consistently, several studies have shown that serine proteases are potential 
BBI targets in prevention and therapy; however, these targets have not been proven thus far. 
The validation of specific serine proteases as BBI targets will contribute to the assessment of 
BBI as chemopreventive agents that may be used in preventive and/or therapeutic medicine.  
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